Manufacture of Asymmetric Hydrogenation Catalysts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacture of Asymmetric Hydrogenation Catalysts
Single-enantiomer drugs represent an increasingly large share of new chemical entities, leading to approaches in asymmetric synthesis.


Pharmaceutical Technology


14. M.J. Burk, "C2-Symmetric Bis(phospholanes) and their Use in Highly Enantioselective Hydrogenation Reactions," J. Am. Chem. Soc. 113 (22), 8518–8519 (1991).

15. S.J.C. Taylor et al., "Choice of Biocatalyst in the Development of Industrial Biotransformations," in Stereoselective Biocatalysis, R.N. Patel, Ed. (Marcel Dekker, New York, 2000), p. 397–413.

16. U. Berens, "Process for Preparing Cyclic Phosphines," US Patent 6545183, 1999.

17. U. Berens, M.J. Burk, and A. Gerlach, "Chiral 1,1-Diphosphetanylferrocenes: New Ligands for Asymmetric Catalytic Hydrogenation of Itaconate Derivatives," Angew. Chem. Int. Ed. 39 (11), 1981–1984 (2000).

18. M.Green, T.A. Kuc, and S.H.J. Taylor, J. Chem. Soc (D) Chem. Comm. (22), 1553–1554 (1970).

19. J.A. Ramsden and P.H. Moran, "Process for Preparting Catonic Rhodium Complexes," Patent WO 2005032712, Chem. Abstr. 142, 394141 (2005).

20. I. Appleby, I. et. al., "Efficient Synthesis of an Imidazole-Substituted δ-Amino Acid by the Integration of Chiral Technologies," Org. Lett. 7 (10), 1931–1934 (2005).

21. D. Chaplin et al., "Industrially Viable Syntheses of Highly Enantiomerically Enriched 1-Aryl Alcohols via Asymmetric Hydrogenation," Org. Process Res. Dev. 7 (1), 89–94 (2003).

22. H. Doucet, et al., "Trans-[RuCl2(phosphane)2(1,2-diamine)] and Chiral trans-[RuCl2 (diphosphane)(1,2-diamine)]: Shelf-Stable Precatalysts for the Rapid, Productive, and Stereoselective Hydrogenation of Ketones," Angew. Chem. Int. Ed. 37 (12), 1703–1707 (1998).

23. P.H.Moran, "Process for Making Diphosphine-Ruthenium Diamine Complexes," WO Patent 2007005550, Chem. Abstr. 146, 133961 (2007).

24. M.T. Reetz and X. Li, "An Efficient Catalyst System for the Asymmetric Transfer Hydrogenation of Ketones: Remarkably Broad Substrate Scope," J. Am. Chem. Soc. 128 (4), 1044–1045 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here